Home›Companies›Biotech & Pharma›Jabez Biosciences

Jabez Biosciences, Inc.

Develops cancer drugs for people with solid tumors and blood cancers.

Updated Nov 10, 2026·Latest SEC filing Mar 26, 2026·Suggest an edit

About Jabez Biosciences

Jabez Biosciences is a private company based in Cranberry Twp., Pennsylvania, incorporated in 2024 in Florida. It has reported $1,608,210 raised in three offerings on Form D since March 2026. Its chief executive is Tamara Jovonovich.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 11, 2024Mar 26, 2026$31,200target not set8$3,900EquityRule 506(b)Form D ↗
Nov 11, 2024Oct 21, 2025amended Oct 28, 2025$250,510target not set3$83,503EquityRule 506(b)Form D/A ↗1 earlier filing
Aug 7, 2024Oct 21, 2025$1,326,500of $3.0M target18$73,694EquityRule 506(b)Form D ↗
Total, three offerings$1,608,210

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Jabez Biosciences's Form D filed Mar 26, 2026.

ML
RL
Robert Lewis
Executive officer, director and promoter
Tamara Jovonovich
Tamara Jovonovich
CEO & Co-Founder, director
DM
ML
Martin Lewis
Director
Brian Cogley
Brian Cogley
CFO and director
BC

Sources

  1. SECJabez Biosciences, Inc. Form D, filed Oct 21, 2025
  2. SECJabez Biosciences, Inc. filing history
  3. CompanyAbout Jabez Biosciences
  4. CompanyMulti-institutional team awarded NCI grant